Esperion Therapeutics Inc. | Ownership
Companies that own Esperion Therapeutics Inc.
Bellevue Asset Management AG
3,282,964
12.25%
-213,520
2.35%
08/03/2018
Meditor Capital Management Ltd.
2,629,835
9.81%
40,600
24.55%
06/30/2018
Tavistock Life Sciences Co. (Investment Management)
2,575,100
9.61%
1,507,513
8.74%
06/30/2018
Partner Fund Management LP
2,492,405
9.3%
1,346,297
2.14%
06/30/2018
Pentwater Capital Management LP
2,464,000
9.19%
153,500
1.77%
06/30/2018
SSgA Funds Management, Inc.
2,173,737
8.11%
859,024
0.01%
06/30/2018
BlackRock Fund Advisors
1,681,024
6.27%
280,433
0%
06/30/2018
The Vanguard Group, Inc.
1,503,261
5.61%
52,202
0%
06/30/2018
Credit Suisse Securities (USA) LLC (Broker)
1,093,599
4.08%
8,779
0.07%
06/30/2018
Fidelity Management & Research Co.
922,979
3.44%
-802,190
0.01%
06/30/2018
| Address |
3891 Ranchero Drive
Ann Arbor Michigan 48108
United States
|
|
Employees
|
- |
| Website |
http://www.esperion.com |
| Updated |
07/08/2019 |
| Esperion Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). It offers Bempedoic acid and Ezetime combination pill as therapies that have been shown to lower elevated LDL-C levels in patients with hypercholesterolemia, including patients inadequately treated with current lipid-modifying therapies. The company was founded by Roger S. |
